Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.


Stock Quote

Jan 28, 2020 /

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events

More events are coming soon.

Upcoming events (more)

Press Releases

16 January 2020

BioNTech to acquire Neon to strengthen global leadership position in T cell the..

13 January 2020

BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Cont..

2 January 2020

BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell..

Press releases (more)